SouthernWorldwide.com – Hershey, the renowned confectionery company, is experiencing an unexpected surge in sales for its mint and gum products, driven by a new consumer trend linked to GLP-1 weight-loss medications.
Hershey’s CEO, Kirk Tanner, revealed during the company’s first-quarter earnings call that while these appetite-suppressing drugs are causing consumers to eat smaller portions of snacks, they are also increasing the demand for breath-freshening products.
Read more : Judge "Deeply Concerned" by Jail Conditions of Dinner Attack Suspect
Tanner stated that the company has observed robust demand for its gum and mint offerings, attributing this growth to the “functional snacking” trend, which includes the rising adoption of GLP-1 drugs. He specifically highlighted that sales for Hershey’s Ice Breakers brand, encompassing both mints and gum, saw an 8% increase during the quarter.
A potential reason behind this phenomenon is the reported side effect of bad breath, sometimes referred to as “Ozempic breath,” experienced by some users of GLP-1 medications like Ozempic and Wegovy. Medical professionals have noted this connection.
Dr. Neha Lalani, speaking to the medical information provider Healthline, described “Ozempic breath” as a fishy smell associated with burps or general bad breath. This term has gained traction among users and observers of these weight-loss drugs.
It is important to note that makers of GLP-1 drugs do not list bad breath, or halitosis, as an official side effect. Doctors also emphasize that “Ozempic breath” is not a formal clinical diagnosis, and the actual impact of these drugs on patients’ oral hygiene is still a subject of ongoing research and study.
In a clinical trial conducted by Novo Nordisk, the manufacturer of Ozempic and Wegovy, a significant portion of participants reported certain side effects. Approximately 9% of individuals taking GLP-1 medications experienced “eructation,” commonly known as burping. Other reported side effects included nausea in over 40% of participants and vomiting in nearly 25% of those taking the drugs.
